Bank of America
SABS icon

Bank of America’s SAB Biotherapeutics SABS Stock Holding History

Bank of America’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$213K Buy
55,697
+45,084
+425% +$180K ﹤0.01% 5329
2025
Q4 		$39.7K Buy
10,613
+10,539
+14,242% +$34.7K ﹤0.01% 5902
2025
Q3 		$149 Buy
74
+1
+1% +$2 ﹤0.01% 7781
2025
Q2 		$128 Buy
73
+6
+9% +$10 ﹤0.01% 7928
2025
Q1 		$91 Buy
67
+3
+5% +$7 ﹤0.01% 7849
2024
Q4 		$243 Sell
64
-33
-34% -$108 ﹤0.01% 7554
2024
Q3 		$262 Sell
97
-68
-41% -$188 ﹤0.01% 7513
2024
Q2 		$511 Buy
+165
New +$605 ﹤0.01% 7357
2024
Q1 		– Sell
-5
Closed -$38 – 8122
2023
Q4 		$38 Buy
+5
New +$42 ﹤0.01% 7552
2023
Q1 		– Sell
-4
Closed -$22 – 8209
2022
Q4 		$22 Sell
4
-43
-91% -$393 ﹤0.01% 7970
2022
Q3 		$0 Sell
47
-31
-40% -$308 ﹤0.01% 8147
2022
Q2 		$1K Sell
78
-200
-72% -$4.2K ﹤0.01% 7886
2022
Q1 		$10K Buy
278
+61
+28% +$2.82K ﹤0.01% 7748
2021
Q4 		$16K Buy
+217
New +$20.4K ﹤0.01% 7589

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bank of America's SABS Position: Q1 2026 in Review

Bank of America increased its SAB Biotherapeutics (SABS) stake by 425% in Q1 2026, buying an estimated $180K and bringing the position to 55,697 shares worth $213K. The position accounts for ﹤0.01% of the portfolio, ranked #5329.

Bank of America first reported a position in SABS in Q4 2021 and has held it in 14 quarters since. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Bank of America held 55,697 shares of SAB Biotherapeutics worth $213K as of Q1 2026.
  • Bank of America bought 45,084 SAB Biotherapeutics shares in Q1 2026, an estimated $180K.
  • SAB Biotherapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5329 holding.
  • Bank of America first reported a position in SAB Biotherapeutics in Q4 2021 and has held it in 14 quarters since.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.